- Previous Close
15.92 - Open
15.53 - Bid 14.88 x 100
- Ask 15.09 x 100
- Day's Range
14.64 - 15.76 - 52 Week Range
9.60 - 18.00 - Volume
97,533 - Avg. Volume
48,669 - Market Cap (intraday)
628.756M - Beta (5Y Monthly) 0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-1.59 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
28.72
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
oculis.comRecent News: OCS
View More
Performance Overview: OCS
Trailing total returns as of 11/12/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OCS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OCS
View MoreValuation Measures
Market Cap
626.18M
Enterprise Value
493.76M
Trailing P/E
63.97
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.89
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.46%
Return on Equity (ttm)
-69.33%
Revenue (ttm)
868k
Net Income Avi to Common (ttm)
-69.62M
Diluted EPS (ttm)
-1.59
Balance Sheet and Cash Flow
Total Cash (mrq)
105.47M
Total Debt/Equity (mrq)
1.30%
Levered Free Cash Flow (ttm)
--
Research Analysis: OCS
View MoreCompany Insights: OCS
OCS does not have Company Insights